INFIQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INFIQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Infinity Pharmaceuticals's share price is $0.0001. Infinity Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Infinity Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Infinity Pharmaceuticals was 19.52. The lowest was 1.02. And the median was 7.87.
As of today (2024-04-25), Infinity Pharmaceuticals's share price is $0.0001. Infinity Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.46. Therefore, Infinity Pharmaceuticals's PE Ratio for today is At Loss.
As of today (2024-04-25), Infinity Pharmaceuticals's share price is $0.0001. Infinity Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.47. Therefore, Infinity Pharmaceuticals's PE Ratio without NRI for today is At Loss.
During the past 13 years, Infinity Pharmaceuticals's highest PE Ratio without NRI was 6.30. The lowest was 0.00. And the median was 5.70.
The historical data trend for Infinity Pharmaceuticals's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinity Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Infinity Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Infinity Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Infinity Pharmaceuticals's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Infinity Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 0.0001 | / | -0.48 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinity Pharmaceuticals (OTCPK:INFIQ) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Adelene Q Perkins | director, officer: President & CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Stephane Peluso | officer: Chief Scientific Officer | 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Robert Jr. Ilaria | officer: Chief Medical Officer | 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Jeffery Kutok | officer: Chief Scientific Officer | 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Samuel Agresta | officer: Chief Medical Officer | 784 MEMORIAL DR., CAMBRIDGE MA 02139 |
David W Beier | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Lawrence E Bloch | officer: EVP, CFO & CBO | |
Michael Kauffman | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael C Venuti | director |
From GuruFocus
By PRNewswire • 09-12-2023
By PRNewswire • 08-26-2023
By Marketwired • 08-26-2023
By PRNewswire • 09-16-2023
By Marketwired • 08-28-2023
By Marketwired • 09-29-2023
By PRNewswire • 09-02-2023
By Marketwired • 10-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.